Targeting a key immune protein to improve treatment for acute respiratory distress syndrome.
Official title: Targeting CD14: A Novel Therapeutic Approach for Acute Respiratory Distress Syndrome
Funded at University of Washington · NIH-10948018 · Data updated 2026-11-12
This study is looking at how a special treatment can help people with acute respiratory distress syndrome (ARDS) by blocking a protein called CD14, which might help calm down the overactive immune response in their lungs, especially for those with COVID-19.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $186,408 |
| NIH project number | 1K23HL175255-01 |
| Project ID | NIH-10948018 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with acute respiratory distress syndrome, particularly those with severe cases or those affected by COVID-19.
✕Less likely to help
Patients with mild respiratory issues or those not diagnosed with ARDS may not benefit from this research.
What this research studies
This research investigates the role of CD14, a protein involved in the immune response, in the treatment of acute respiratory distress syndrome (ARDS). The approach focuses on blocking CD14 to potentially regulate the immune response in the lungs, which can become overactive during ARDS. By using a monoclonal antibody called IC14, the research aims to reduce inflammation and improve clinical outcomes for patients suffering from ARDS, including those affected by COVID-19. The study will also explore a biomarker that may help predict which patients will respond best to this treatment.
Why it matters
Potential benefit: If successful, this research could lead to a new therapeutic option that significantly improves survival rates and recovery for patients with ARDS.
How similar studies have gone: Previous studies have shown promising trends in mortality benefits when targeting CD14 in COVID-19 related ARDS, suggesting potential for success in this broader application.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Mabrey, Frances Linzee — University of Washington
- Study coordinator: Mabrey, Frances Linzee
Related research
Other NIH-funded projects on the same topics.
-
Identifying ARDS patients who may benefit from paralytics guided by high-frequency clinical data
This grant aims to help doctors figure out which adults with ARDS are most likely to benefit from paralytic medications using detailed bedside data and electronic health records.
-
Resilience endotypes and early ARDS detection using biomarkers and AI
A Duke University team is using biomarkers and smart data analysis to detect ARDS early and uncover patterns that predict how patients recover.
-
PAR1’s role in lung lymphatics and a new therapy approach for ARDS
This grant explores how the thrombin receptor PAR1 affects lung lymphatics to understand and ultimately reduce lung injury in ARDS patients.
-
Dead space and inhaled nitric oxide in pediatric ARDS
This project looks at whether measuring dead space and using inhaled nitric oxide can help improve outcomes for children with acute respiratory distress syndrome.
-
Immune, hormone, and muscle energy links to recovery after ARDS
This project looks at why some ARDS survivors have ongoing weakness and how immune, hormone, and muscle energy factors might influence recovery.</n>
-
Understanding why some people with severe lung injury get worse and how to tailor therapy
A patient-focused program that looks at why people develop sepsis-associated ARDS and how their bodies respond, with the goal of guiding better, personalized treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.